| Peer-Reviewed

Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination

Received: 15 September 2022     Accepted: 4 October 2022     Published: 17 October 2022
Views:       Downloads:
Abstract

Switching to dolutegravir (DTG)-based triple therapy is done without taking into account the level of viral replication and resistance developed by the virus against nucleoside reverse transcriptase inhibitors (NRTIs). The objective of the study was to evaluate the resistance to NRTIs in children and adults with virological failure in Côte d'Ivoire in a context of systematic switching to a DTG-based combination. The study population was constituted at the Abidjan Integrated Bioclinical Research Center (CIRBA) from a cohort of children in virological failure from 2012 to 2013 and HIV-1 infected adults with an indication for genotypic resistance testing from 2015 to 2017. Biological analyses were performed using ANRS techniques and algorithm (www.hivfrenchresistance.org). A total of 243 children and adults with virological failure were included in the study. The frequency of resistance to NRTIs was 65% (n = 159/243). It was 92% (n = 146/159) to lamivudine/emtricitabine (3TC/FTC), 52% (n= 82/159) to zidovudine (ZDV), 45% (n = 71/159) to abacavir (ABC) and 18% (n = 29/159) to tenofovir (TDF). Commonly encountered mutations were M184V/I (90%; n = 143/159) for 3TC/FTC, T215I/N/V/Y/F (42%; n = 67/159) for ZDV, L74V/I (22%; n = 35/159) for ABC. K65R (4%; n = 6/159) and K70E (6%; n = 9/159) for TDF. This study highlights the need to guide the switch to triple therapy containing two NRTIs and one dolutegravir molecule by genotypic resistance testing.

Published in Biochemistry and Molecular Biology (Volume 7, Issue 4)
DOI 10.11648/j.bmb.20220704.11
Page(s) 70-74
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

HIV-1, NRTI Resistance Mutation, Switched to Dolutegravir (DTG) Therapy

References
[1] Myburgh, H., Reynolds, L., Hoddinott, G., van Aswegen, D., Grobbelaar, N., Gunst, C., Jennings, K., Kruger, J., Louis, F., Mubekapi-Musadaidzwa, C., Viljoen, L., Wademan, D., & Bock, P. (2021). Implementing 'universal' access to antiretroviral treatment in South Africa: a scoping review on research priorities. Health Policy Plan, 36 (6), 923-938. doi: 10.1093/heapol/czaa094.
[2] De Clercq, J., Rutsaert, S., De Scheerder, M.-A., Verhofstede, C., Callens, S., & Vandekerckhove, L. (2020). Benefits of antiretroviral therapy initiation during acute HIV infection. Acta Clinica Belgica, 77 (1), 168-176. doi: 10.1080/17843286.2020.1770413.
[3] Ministry of Health and Public Hygiene (MSHP). The “Test and Treat All” approach in the context of the Care and Support of PLHIV in Côte d’Ivoire. Circular Note N°0001/MSHP/DGS/PNLS/DC of 07 February 2017 for the attention of Health Providers.
[4] World Health Organization (WHO). Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019 (WHO/CDS/HIV/19.15). Licence: CC BY-NC-SA 3.0 IGO. Available at: https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1; 2019
[5] Mbhele, N., Chimukangara, B., & Gordon, M. (2021). HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. International Journal of Antimicrobial Agents, 57 (5), 106343. doi: 10.1016/j.ijantimicag.2021.106343.
[6] Laskey, S. B. & Siliciano, R. F. (2016). Quantitative evaluation of the antiretroviral efficacy of dolutegravir. JCI Insight, 1 (19): e90033. doi: 10.1172/jci.insight.90033.
[7] Pham, H., T., Mesplède, T., & Wainberg, M., A. (2016). Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses. Retrovirology, 13 (1), 31. doi: 10.1186/s12977-016-0265-x.
[8] Malet, I., Thierry, E., Wirden, M., Lebourgeois, S., Subra, F., Katlama, C., Deprez, E., Calvez, V., Marcelin, A., G., & Delelis, O. (2015). Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. J Antimicrob Chemother, 70 (10), 2870-80. doi: 10.1093/jac/dkv197.
[9] Ndashimye, E., & Arts, E. J. (2021). Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings. International Journal of Infectious Diseases, 105, 298–303. doi: 10.1016/j.ijid.2021.03.018.
[10] Blanco, J. L., Rojas, J., Paredes, R., Negredo, E., Mallolas, J., Casadella, M., Clotet, B., Gatell, J. M., de Lazzari, E., Martinez, E., & DOLAM Study Team (2018). Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. The Journal of antimicrobial chemotherapy, 73 (7), 1965–1971. https://doi.org/10.1093/jac/dky093.
[11] Hocqueloux, L., Raffi, F., Prazuck, T., Bernard, L., Sunder, S., Esnault, J. L., Rey, D., Le Moal, G., Roncato-Saberan, M., André, M., Billaud, E., Valéry, A., Avettand-Fènoël, V., Parienti, J. J., Allavena, C., & MONCAY study group (2019). Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 69 (9), 1498–1505. https://doi.org/10.1093/cid/ciy1132
[12] Nagami, E. H., Thakarar, K., & Sax PE. (2021). Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance. Open Forum Infectious Diseases, 9 (2), ofab648. doi: 10.1093/ofid/ofab648.
[13] Wijting, I., Rokx, C., Boucher, C., van Kampen, J., Pas, S., de Vries-Sluijs, T., Schurink, C., Bax, H., Derksen, M., Andrinopoulou, E. R., van der Ende, M., van Gorp, E., Nouwen, J., Verbon, A., Bierman, W., & Rijnders, B. (2017). Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. The lancet. HIV, 4 (12), e547–e554. https://doi.org/10.1016/S2352-3018(17)30152-2
Cite This Article
  • APA Style

    Dechi Jean-Jacques Renaud, Toni Thomas D'Aquin, Cisse-Camara Massara, N'din Jean-Louis Philippe, Ake Aya Jeanne Armande, et al. (2022). Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochemistry and Molecular Biology, 7(4), 70-74. https://doi.org/10.11648/j.bmb.20220704.11

    Copy | Download

    ACS Style

    Dechi Jean-Jacques Renaud; Toni Thomas D'Aquin; Cisse-Camara Massara; N'din Jean-Louis Philippe; Ake Aya Jeanne Armande, et al. Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochem. Mol. Biol. 2022, 7(4), 70-74. doi: 10.11648/j.bmb.20220704.11

    Copy | Download

    AMA Style

    Dechi Jean-Jacques Renaud, Toni Thomas D'Aquin, Cisse-Camara Massara, N'din Jean-Louis Philippe, Ake Aya Jeanne Armande, et al. Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochem Mol Biol. 2022;7(4):70-74. doi: 10.11648/j.bmb.20220704.11

    Copy | Download

  • @article{10.11648/j.bmb.20220704.11,
      author = {Dechi Jean-Jacques Renaud and Toni Thomas D'Aquin and Cisse-Camara Massara and N'din Jean-Louis Philippe and Ake Aya Jeanne Armande and Siransy Kouabla Liliane and Sekongo Yassongui Mamadou and Gogbe Leto Olivier and Brou Emmanuel and Fieni Flore and Wawa Amedee Junior and Aby Roland and Kouakou Kouadio and Chenal Henri},
      title = {Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination},
      journal = {Biochemistry and Molecular Biology},
      volume = {7},
      number = {4},
      pages = {70-74},
      doi = {10.11648/j.bmb.20220704.11},
      url = {https://doi.org/10.11648/j.bmb.20220704.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bmb.20220704.11},
      abstract = {Switching to dolutegravir (DTG)-based triple therapy is done without taking into account the level of viral replication and resistance developed by the virus against nucleoside reverse transcriptase inhibitors (NRTIs). The objective of the study was to evaluate the resistance to NRTIs in children and adults with virological failure in Côte d'Ivoire in a context of systematic switching to a DTG-based combination. The study population was constituted at the Abidjan Integrated Bioclinical Research Center (CIRBA) from a cohort of children in virological failure from 2012 to 2013 and HIV-1 infected adults with an indication for genotypic resistance testing from 2015 to 2017. Biological analyses were performed using ANRS techniques and algorithm (www.hivfrenchresistance.org). A total of 243 children and adults with virological failure were included in the study. The frequency of resistance to NRTIs was 65% (n = 159/243). It was 92% (n = 146/159) to lamivudine/emtricitabine (3TC/FTC), 52% (n= 82/159) to zidovudine (ZDV), 45% (n = 71/159) to abacavir (ABC) and 18% (n = 29/159) to tenofovir (TDF). Commonly encountered mutations were M184V/I (90%; n = 143/159) for 3TC/FTC, T215I/N/V/Y/F (42%; n = 67/159) for ZDV, L74V/I (22%; n = 35/159) for ABC. K65R (4%; n = 6/159) and K70E (6%; n = 9/159) for TDF. This study highlights the need to guide the switch to triple therapy containing two NRTIs and one dolutegravir molecule by genotypic resistance testing.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination
    AU  - Dechi Jean-Jacques Renaud
    AU  - Toni Thomas D'Aquin
    AU  - Cisse-Camara Massara
    AU  - N'din Jean-Louis Philippe
    AU  - Ake Aya Jeanne Armande
    AU  - Siransy Kouabla Liliane
    AU  - Sekongo Yassongui Mamadou
    AU  - Gogbe Leto Olivier
    AU  - Brou Emmanuel
    AU  - Fieni Flore
    AU  - Wawa Amedee Junior
    AU  - Aby Roland
    AU  - Kouakou Kouadio
    AU  - Chenal Henri
    Y1  - 2022/10/17
    PY  - 2022
    N1  - https://doi.org/10.11648/j.bmb.20220704.11
    DO  - 10.11648/j.bmb.20220704.11
    T2  - Biochemistry and Molecular Biology
    JF  - Biochemistry and Molecular Biology
    JO  - Biochemistry and Molecular Biology
    SP  - 70
    EP  - 74
    PB  - Science Publishing Group
    SN  - 2575-5048
    UR  - https://doi.org/10.11648/j.bmb.20220704.11
    AB  - Switching to dolutegravir (DTG)-based triple therapy is done without taking into account the level of viral replication and resistance developed by the virus against nucleoside reverse transcriptase inhibitors (NRTIs). The objective of the study was to evaluate the resistance to NRTIs in children and adults with virological failure in Côte d'Ivoire in a context of systematic switching to a DTG-based combination. The study population was constituted at the Abidjan Integrated Bioclinical Research Center (CIRBA) from a cohort of children in virological failure from 2012 to 2013 and HIV-1 infected adults with an indication for genotypic resistance testing from 2015 to 2017. Biological analyses were performed using ANRS techniques and algorithm (www.hivfrenchresistance.org). A total of 243 children and adults with virological failure were included in the study. The frequency of resistance to NRTIs was 65% (n = 159/243). It was 92% (n = 146/159) to lamivudine/emtricitabine (3TC/FTC), 52% (n= 82/159) to zidovudine (ZDV), 45% (n = 71/159) to abacavir (ABC) and 18% (n = 29/159) to tenofovir (TDF). Commonly encountered mutations were M184V/I (90%; n = 143/159) for 3TC/FTC, T215I/N/V/Y/F (42%; n = 67/159) for ZDV, L74V/I (22%; n = 35/159) for ABC. K65R (4%; n = 6/159) and K70E (6%; n = 9/159) for TDF. This study highlights the need to guide the switch to triple therapy containing two NRTIs and one dolutegravir molecule by genotypic resistance testing.
    VL  - 7
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • National Blood Transfusion Center (CNTS), Abidjan, Ivory Coast

  • Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast

  • Unit of Training and Research in Medical Sciences, Felix Houphouet Boigny University, Abidjan, Ivory Coast

  • Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast

  • National Blood Transfusion Center (CNTS), Abidjan, Ivory Coast

  • National Blood Transfusion Center (CNTS), Abidjan, Ivory Coast

  • National Blood Transfusion Center (CNTS), Abidjan, Ivory Coast

  • Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast

  • Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast

  • Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast

  • Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast

  • Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast

  • Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast

  • Integrated Center for Bioclinical Research of Abidjan (CIRBA), Abidjan, Ivory Coast

  • Sections